Foreign medical device manufacturers planning to enter the Indian market must understand the role of an EU Free Sale Certificate (FSC) in CDSCO medical device registration. An EU FSC can serve as important regulatory evidence in an Indian import-licence application, but it does not by itself constitute approval to market a medical device in India.
Under India's Medical Devices Rules, 2017 (MDR 2017), foreign manufacturers must comply with the Indian regulatory framework applicable to the device, including classification, appointment of an authorised Indian agent, technical documentation, labelling, quality-system requirements and the applicable CDSCO import-licensing process.
CDSCO's current import-licence checklist for a fresh Form MD-14 application identifies a Free Sale Certificate or Marketing Authorisation issued by the National Regulatory Authority of the country of origin, where available, as well as a Free Sale Certificate or Marketing Authorisation issued by the National Regulatory Authority of specified jurisdictions, including the European Union, United States, United Kingdom, Canada, Japan and Australia. The checklist specifies duly notarised copies for these regulatory certificates.
An EU Free Sale Certificate for a medical device is regulatory evidence concerning the device's ability to be marketed in the relevant European regulatory jurisdiction. For an Indian CDSCO application, the FSC is supporting documentation rather than an Indian marketing authorisation.
It is important to distinguish between:
A CE mark or EU FSC does not automatically authorise the sale or distribution of a medical device in India. The foreign manufacturer must still satisfy the applicable Indian requirements and obtain the appropriate CDSCO import licence.
For a foreign manufacturer's Form MD-14 application, the CDSCO checklist includes regulatory certificates such as a Free Sale Certificate or Marketing Authorisation from the country of origin, where applicable, and from specified reference jurisdictions. The current CDSCO checklist expressly includes the EU among those jurisdictions.
The exact documents required should therefore be assessed against the current CDSCO checklist and the characteristics and regulatory status of the particular device.
An EU FSC should not be treated as a substitute for the complete technical dossier.
An EU FSC and CE-marking documentation serve different regulatory purposes.
For an EU medical device, the manufacturer may have documents such as:
CDSCO's import checklist separately identifies the FSC/Marketing Authorisation, quality-system evidence, applicable CE/conformity-assessment certificates and the manufacturer's Declaration of Conformity.
Therefore, an EU FSC should not be described as "proof of CE acceptance by CDSCO." Rather, it is one component of the regulatory evidence that may support the Indian import-licensing application.
The Indian regulatory pathway generally involves the following key steps:
The first step is to determine the applicable risk class under the Medical Devices Rules, 2017.
Medical devices in India are classified into:
Classification affects the regulatory pathway, documentation and level of regulatory scrutiny.
Foreign manufacturers should establish the classification before preparing the final CDSCO dossier.
A foreign manufacturer must appoint an Authorised Indian Agent to undertake the regulatory activities in India in accordance with the MDR 2017 requirements.
The CDSCO import-licence checklist requires documentation relating to the authorised agent, including a copy of the applicable wholesale licence, manufacturing licence or Form MD-42 registration certificate, together with constitution details.
The manufacturer should also execute the required Power of Attorney in the prescribed manner.
The CDSCO checklist specifies authentication requirements for the Power of Attorney, including authentication in India by a Magistrate of First Class, the Indian Embassy in the country of origin or an equivalent authority through apostille.
Authentication requirements for individual documents should always be checked against the current CDSCO checklist rather than applying the POA requirement automatically to every document.
The CDSCO import application requires substantially more than an FSC.
The current checklist includes, among other documents:
The exact dossier should be prepared according to the applicable device category and current CDSCO requirements.
A well-prepared CDSCO dossier should contain the required manufacturing and device information in the format prescribed by the Fourth Schedule of the Medical Devices Rules, 2017.
The Plant Master File provides information concerning the manufacturing site and manufacturing activities.
Depending on the applicable requirements, it may include information relating to:
The Device Master File contains technical information about the specific medical device.
The CDSCO checklist identifies the Device Master File under Appendix II of the Fourth Schedule and includes areas such as:
The DMF should be consistent with the manufacturer's EU technical documentation while also addressing Indian regulatory requirements.
An EU FSC can strengthen the regulatory documentation supporting an import application by demonstrating the device's regulatory status in the relevant jurisdiction.
However, it is important to understand what the FSC does not do.
An EU FSC does not:
Instead, the FSC should be incorporated into the wider regulatory dossier.
A significant recent development for EU medical device manufacturers is G.S.R. 744(E), dated 14 August 2026.
CDSCO identifies this notification as an amendment to the Medical Devices Rules, 2017 concerning the inclusion of EU countries in Rule 63 and quality-management-system requirements for certain Class A non-sterile, non-measuring devices.
This amendment is particularly relevant when assessing the clinical-evidence pathway for eligible EU-regulated devices.
However, the amendment should not be interpreted to mean that every CE-marked medical device automatically receives a clinical-investigation exemption in India.
The applicability of Rule 63 depends on the statutory conditions, the regulatory status of the device, the available safety and performance evidence and the assessment of the Central Licensing Authority.
Therefore, manufacturers should assess Rule 63 on a device-specific basis rather than assuming that an EU FSC or CE mark automatically removes Indian clinical requirements.
Clinical evidence requirements depend on several factors, including:
An EU FSC can provide useful regulatory evidence, but it should not be represented as a universal clinical-data waiver.
For higher-risk Class C and Class D medical devices, manufacturers should expect more extensive regulatory assessment and should prepare appropriate clinical and performance evidence.
Where Rule 63 or another applicable MDR provision provides a specific pathway based on foreign regulatory approval, the manufacturer should demonstrate that all relevant statutory conditions are satisfied.
The CDSCO import checklist requires quality-system evidence for the actual manufacturing site, as applicable. The checklist also identifies documents such as:
Manufacturers should therefore ensure that the quality documentation submitted to CDSCO corresponds to the actual manufacturing site and the regulatory status of the device.
Where ISO 13485 certification is applicable or submitted as supporting evidence, the certificate should accurately identify the relevant manufacturing facility and remain valid.
EU-compliant labelling should not simply be copied into the Indian market without review.
Medical devices imported into India must comply with the applicable Indian labelling requirements under Chapter VI of the Medical Devices Rules, 2017. CDSCO's FAQ confirms that product labels must comply with the labelling requirements prescribed under the Rules.
The manufacturer should therefore review:
Foreign manufacturers must also consider the Indian residual shelf-life requirements before shipping medical devices to India.
CDSCO's FAQ states that Rule 47 specifies the residual shelf-life requirements for imported medical devices. The applicable minimum residual shelf life depends on the total shelf life claimed by the manufacturer:
|
Total shelf life |
Minimum residual shelf life at import |
|
Less than 90 days |
40% |
|
90 days to 1 year |
50% |
|
More than 1 year |
60% |
Manufacturers and importers should incorporate these requirements into their supply-chain and shipment controls.
Obtaining an import licence is not the end of the regulatory process.
The licence holder must continue to comply with applicable post-market obligations. CDSCO's FAQ confirms that the licensed holder is responsible for submission of Post Marketing Surveillance (PMS) data to the Licensing Authority.
Foreign manufacturers should therefore establish procedures for:
For a foreign manufacturer seeking to import medical devices for sale or distribution in India, the application pathway includes Form MD-14, with the resulting import licence issued in Form MD-15 when the application is approved.
The CDSCO checklist identifies the fresh import-licence application as a Form MD-14 application and lists the regulatory and technical documents required for assessment.
The application should be complete and internally consistent before submission because discrepancies between the FSC, CE documentation, manufacturing-site information, PMF, DMF and labelling can result in regulatory queries.
CDSCO fees for medical device applications are prescribed under the applicable fee provisions and schedules.
The actual processing period can vary depending on:
Accordingly, manufacturers should avoid promising a fixed approval timeline unless it is specifically supported by the applicable regulatory provision.
Medical device applications are submitted electronically through the applicable CDSCO online regulatory system and associated government digital platforms.
Manufacturers and authorised agents should use the current CDSCO instructions and application interface applicable at the time of filing because online procedures and government platforms may be updated.
CDSCO provides the relevant medical-device forms, checklists, FAQs, guidance documents and regulatory information through its Medical Device & Diagnostics section.
Foreign manufacturers can reduce regulatory queries by avoiding common documentation problems such as:
Foreign manufacturers often engage a specialist regulatory consultant to coordinate the Indian registration process and maintain consistency across the technical dossier.
MDR Consultants can support foreign manufacturers with:
The objective should be to prepare a complete and internally consistent submission aligned with the applicable CDSCO requirements rather than relying on the EU FSC alone.
An EU Free Sale Certificate can be an important supporting document for CDSCO medical device registration in India, particularly because the current CDSCO import checklist recognises regulatory certificates from the European Union and other specified jurisdictions.
However, an EU FSC does not replace India's regulatory requirements or constitute an Indian marketing authorisation. Foreign manufacturers must also address device classification, authorised-agent requirements, regulatory certificates, quality-system evidence, Plant Master File, Device Master File, Indian labelling, clinical and performance evidence where applicable, residual shelf life and post-market surveillance.
The 14 August 2026 amendment under G.S.R. 744(E) is particularly relevant for EU manufacturers because it amended MDR 2017 to include EU countries within the relevant Rule 63 framework. The amendment should be assessed on a device-specific basis and should not be interpreted as an automatic exemption from Indian clinical requirements for every CE-marked device.
For foreign manufacturers, the most effective approach is therefore to treat the EU FSC as one part of a complete CDSCO regulatory dossier and ensure that every supporting document is consistent with the current Medical Devices Rules, 2017 and CDSCO's latest checklist.
Is an EU Free Sale Certificate required for CDSCO registration?
An FSC or Marketing Authorisation may form part of the regulatory documentation for an import-licence application. The current CDSCO checklist specifically identifies FSC/Marketing Authorisation documents from the country of origin, where applicable, and from specified jurisdictions including the EU.
Does an EU FSC mean that a medical device is automatically approved by CDSCO?
No. An EU FSC is supporting regulatory evidence. The manufacturer must still obtain the applicable Indian CDSCO import licence and satisfy the Medical Devices Rules, 2017.
Does CE marking replace CDSCO registration?
No. CE marking demonstrates compliance with applicable European requirements; it does not itself authorise commercial marketing of the device in India.
Can an EU-approved device avoid an Indian clinical investigation?
Not automatically. The applicability of any clinical-investigation exemption or alternative pathway must be assessed under the relevant MDR provisions. Following G.S.R. 744(E), EU countries have been included in the relevant Rule 63 framework, subject to its statutory conditions.
Is ISO 13485 required for CDSCO medical device registration?
Applicable quality-system evidence must be provided as required for the particular application and device. The current CDSCO import checklist includes quality-system documentation for the actual manufacturing site, as applicable.
What is the residual shelf-life requirement for imported medical devices in India?
Under Rule 47, CDSCO states minimum residual shelf-life requirements of 40%, 50% or 60%, depending on the device's total claimed shelf life.
Last Updated : 28 Sep 2026
The Brand That Promises To Turn Your Business Around!
MDR Consultants excels in guiding medical device companies through global regulatory approvals with tailored solutions, clear communication, and efficient delivery. Their mission-driven approach fosters innovation, compliance, and long-term partnerships built on trust and excellence.
As I observed this company maintains a very good and cooperative environment. "MDR" consultancy is equipped with all modern amenities. They guide you the best. I highly recommend this firm. The entire team is very courteous and helpful. Highly Professional team and the owner is very skilled and humble.
Outstanding expertise! They streamlined our regulatory process, saving us immense time and stress. A truly invaluable partner for medical device compliance.
MDR Consultants have been a reliable partner for our CDSCO registration needs. Their efficient processes and in-depth knowledge of the regulations saved us significant time and resources. We are confident about the quality of their services and their commitment to client satisfaction.
MDR team has consistently delivered quality work, meeting deadlines and exceeding our expectations. We really recommend MDR for regulatory support
My experience with MDR consultants is wonderful. They have in-depth and vast knowledge about their work. They have the team of incredible people. Their commitment towards the client is highly appreciable. I highly recommend to have their services.
MDR IS THE BEST SOLUTION FOR MEDICAL DEVICES CONSULTANCIE THEY PROVIDE ALL THE SOLUTIONS AND PROPER GUIDANCE.AND DELIVER THEIR SERVICES ON TIME .
MDR team has consistently delivered high quality work, meeting deadlines and exceeding our expectations.
It was really a nice experience working with MDR consultancy.They guide you properly with their tranparent work ethics.Honestly MDR consultancy helped me a lot in growing my business.
A very friendly bunch of efficient employees in the team of MDR.A very professional approach towards their job and all my work was done hassle free with least follow up from my side.Keep up great work team MDR!!!!👍👍
The services are top notch , highly recommend for Mr Ashish
Best regulatory services..for medical devices…best in the business
Have a rich experience in the field of consultancy.
Extremely helpful and responsive
Very good experience
Good Services
Appreciable work.
True consultant
Medical Device Regulatory Consultants
37-38, 1st Floor, Near Makhan Bhog, G.T. Road,
Kundli Industrial Area, Delhi NCR, 131028